If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
ARYA Sciences Acquisition III (ARYA)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
Duck Creek Technologies, Inc. (DCT)
Priced IPO
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
More companies

Legend Biotech Corporation (LEGN)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Their team of over 650 employees in the United States, China and Europe, their differentiated technology, global development and manufacturing strategy and expertise provide them with the ability to generate, test and manufacture next-generation cell therapies targeting indications with high unmet needs. Their lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy they are jointly developing with their strategic partner, Janssen Biotech, Inc., or Janssen, for the treatment of multiple myeloma, or MM. They are developing LCAR-B38M/JNJ-4528 as a potentially improved therapy for MM. LCAR-B38M refers to the product candidate being studied in China, and JNJ-68284528, or JNJ-4528, refers to the product candidate being studied in the rest of the world. Their clinical results achieved to date demonstrate that LCAR-B38M/JNJ-4528 has the potential to deliver deep and durable anti-tumor responses in relapsed and refractory multiple myeloma, or RRMM, patients with a manageable safety profile.
Yuan Xu Ying Huang
Employees Founded
645 2014


Address: 2101 Cottontail Lane, Somerset, NJ 08873, US

Telephone: (732) 317-5050

Web page:

IPO information

Expected Date 6/5/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $491.5
Revenues (MM) $58.8
Net Income (Loss) (MM) $-164.8


What do you think will happen with the LEGN share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 18.4
Shares Revised (MM) 18.4
Expected offer amount (MM) $349.6
Realized offer amount(MM) $423.2
Morgan Stanley/ JP Morgan/ Jefferies

Sector: Healthcare

Tweets about $LEGN

Tweets volume:

RT volume:


Google Trends Stats